HLA-DRA expression (>1% cutoff for positive versus negative), assessed using the DAKO M0746 antibody, did not predict outcome in either CHOP or R-CHOP cohorts from the large German RICOVER-60 trial.53 The Lunenburg Lymphoma Biomarker Consortium found HLA-DR expression, scored as negative versus positive, predicted OS in one of their two CHOP-treated cohorts and not in CHOP-treated patients who had received rituximab.54 In addition, a recent flow cytometry study of a small series of 36 Japanese patients reported that DLBCL patients with 'not bright' HLA-DR staining had a poor prognosis.55 Here, HLA-DRA is linked to lymphoma.